SANIONA AB (PUBL) (30S) - Total Liabilities
Based on the latest financial reports, SANIONA AB (PUBL) (30S) has total liabilities worth €44.58 Million EUR (≈ $52.12 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 30S cash generation efficiency to assess how effectively this company generates cash.
SANIONA AB (PUBL) - Total Liabilities Trend (2021–2025)
This chart illustrates how SANIONA AB (PUBL)'s total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of SANIONA AB (PUBL) for net asset value and shareholders' equity analysis.
SANIONA AB (PUBL) Competitors by Total Liabilities
The table below lists competitors of SANIONA AB (PUBL) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Landmark Bancorp Inc
NASDAQ:LARK
|
USA | $1.44 Billion |
|
Chime Ball Technology Co Ltd
TWO:1595
|
Taiwan | NT$1.31 Billion |
|
Chia Chang Co Ltd
TW:4942
|
Taiwan | NT$2.71 Billion |
|
CTT Systems AB
ST:CTT
|
Sweden | Skr94.20 Million |
|
TrueBlue Inc
NYSE:TBI
|
USA | $364.59 Million |
|
Heungkuk F&M I
KO:000540
|
Korea | ₩12.24 Trillion |
|
Sonadezi Chau Duc Shareholding Co
VN:SZC
|
Vietnam | ₫5.11 Trillion |
|
1911 Gold Corp
V:AUMB
|
Canada | CA$9.87 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SANIONA AB (PUBL)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is SANIONA AB (PUBL) worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SANIONA AB (PUBL)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SANIONA AB (PUBL) (2021–2025)
The table below shows the annual total liabilities of SANIONA AB (PUBL) from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €44.58 Million ≈ $52.12 Million |
-58.69% |
| 2024-12-31 | €107.92 Million ≈ $126.16 Million |
+25.36% |
| 2023-12-31 | €86.08 Million ≈ $100.64 Million |
-14.76% |
| 2022-12-31 | €100.99 Million ≈ $118.07 Million |
-36.18% |
| 2021-12-31 | €158.25 Million ≈ $185.01 Million |
-- |
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more